ethyl (2S)-2-{[(4aR,6R,7R,7aR)-6-(4-amino-2-oxopyrimidin-1(2H)-yl)-7-hydroxy-7-methyl-2-oxotetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-2-yl]amino}butanoate | 1035637-86-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl (2S)-2-{[(4aR,6R,7R,7aR)-6-(4-amino-2-oxopyrimidin-1(2H)-yl)-7-hydroxy-7-methyl-2-oxotetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-2-yl]amino}butanoate
• 英文别名: Ethyl (2S)-2-{[(4aR,6R,7R,7aR)-6-(4-amino-2-oxopyrimidin-1(2H)-yl)-7-hydroxy-7-methyl-2-oxidotetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-2-yl]amino}butanoate；ethyl (2S)-2-[[(4aR,6R,7R,7aR)-6-(4-amino-2-oxopyrimidin-1-yl)-7-hydroxy-7-methyl-2-oxo-4,4a,6,7a-tetrahydrofuro[3,2-d][1,3,2]dioxaphosphinin-2-yl]amino]butanoate
• CAS: 1035637-86-5
• 化学式: C₁₆H₂₅N₄O₈P
• 分子量: 432.37
• InChiKey: FXXAFXPILCFSHF-FPXRPTHXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  162
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  2,2-二-正丙基乙酰基氯 、 ethyl (2S)-2-{[(4aR,6R,7R,7aR)-6-(4-amino-2-oxopyrimidin-1(2H)-yl)-7-hydroxy-7-methyl-2-oxotetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-2-yl]amino}butanoate 在 4-二甲氨基吡啶 、 三乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以36%的产率得到ethyl (2S)-2-{[(4aR,6R,7R,7aR)-7-hydroxy-7-methyl-2-oxo-6-(2-oxo-4-[(2-propylpentanoyl)amino]pyrimidin-1(2H)-yl)-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-2-yl]amino}butanoate
  参考文献：
  名称：

  WO2008/79206

  摘要：

  公开号：

文献信息

• NUCLEOSIDE CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION
  申请人：Meppen Malte

  公开号：US20100022468A1

  公开（公告）日：2010-01-28

  The present invention provides nucleoside cyclic phosphoramidates of structural formula (I) which are precursors to inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors to inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as pre-cursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside cyclic phosphoramidates alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside cyclic phosphoramidates of the present invention.

  本发明提供了结构式（I）的核苷酸环磷酰胺，它们是RNA依赖性RNA病毒聚合酶抑制剂的前体。这些化合物是RNA依赖性RNA病毒复制的抑制剂的前体，并且可用于治疗RNA依赖性RNA病毒感染。它们特别适用于作为丙型肝炎病毒（HCV）NS5B聚合酶抑制剂的前体，作为HCV复制抑制剂的前体和/或用于治疗丙型肝炎感染。本发明还描述了仅含有这种核苷酸环磷酰胺或与其他对RNA依赖性RNA病毒感染，特别是HCV感染活性的药物组合的制药组合物。本发明还公开了使用本发明的核苷酸环磷酰胺抑制RNA依赖性RNA聚合酶，抑制RNA依赖性RNA病毒复制和/或治疗RNA依赖性RNA病毒感染的方法。
• Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection
  申请人：Istituto di Ricerche di Biologia Molecolare P. Angeletti S.P.A.

  公开号：US08148349B2

  公开（公告）日：2012-04-03

  The present invention provides nucleoside cyclic phosphoramidates of formula (I), pharmaceutical compositions comprising the compounds of formula (I) and methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection using the compounds of formula (I).

  本发明提供了式(I)的核苷酸环磷酰胺，包括式(I)化合物的制药组合物以及使用式(I)化合物抑制RNA依赖性RNA聚合酶，抑制RNA依赖性RNA病毒复制和/或治疗RNA依赖性RNA病毒感染的方法。
• US8148349B2
  申请人：——

  公开号：US8148349B2

  公开（公告）日：2012-04-03
• WO2008/79206
  申请人：——

  公开号：——

  公开（公告）日：——